Amylyx Pharmaceuticals Inc (AMLX)
1.76
-0.02
(-1.12%)
USD |
NASDAQ |
Apr 26, 16:00
1.755
0.00 (0.00%)
After-Hours: 20:00
Amylyx Pharmaceuticals Cash from Operations (TTM): 11.92M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 11.92M |
| September 30, 2023 | -51.33M |
| June 30, 2023 | -89.24M |
| March 31, 2023 | -144.31M |
| December 31, 2022 | -179.87M |
| Date | Value |
|---|---|
| September 30, 2022 | -158.42M |
| June 30, 2022 | -136.20M |
| March 31, 2022 | -102.79M |
| December 31, 2021 | -74.80M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-179.87M
Minimum
Dec 2022
11.92M
Maximum
Dec 2023
-102.78M
Average
-102.79M
Median
Mar 2022
Cash from Operations (TTM) Benchmarks
| Cassava Sciences Inc | -82.02M |
| iRhythm Technologies Inc | -50.10M |
| Bristol-Myers Squibb Co | 13.72B |
| Moderna Inc | -3.118B |
| ACADIA Pharmaceuticals Inc | 16.70M |